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Introduction
The use of fat to improve contour irregularities and cor-
rect depressions goes back to the end of the nineteenth 
Century when gustav neuber (1850-1932) described the 
first transplantation of parcels of arm adipose tissue to 
the lower margin of the orbit as a means of improving 
adherent  scars  due  to  osteomyelitis1.  Thereafter,  many 
Authors 2 3 described the advantages to be obtained from 
fat grafting for various clinical applications in functional/
reconstructive and cosmetic surgery.
however, the technique fell out of favour because the ten-
dency of the grafts to resorb, form cysts and be almost 
completely replaced by fibrous tissue, made the results 
unpredictable, especially in the field of facial aesthetics.
The advent of liposuction, in the early 1980s, renewed in-
terest in autologous fat re-injection 4 but, despite numerous 
attempts, the injected lipoaspirate continued to disappear al-
most completely. The problems of reabsorption were finally 
overcome in the 1990s, when Sidney Coleman developed 
a new atraumatic technique for fat harvesting and place-
ment 5 that preserved the fragile adipocytes. in his opinion, 
the keys for success were: 1) harvesting with low negative 
pressure; 2) purifying the lipoaspirate by centrifugation; 
and 3) placing minimal amounts of adipocytes in multiple 
tunnels in order to maximise contact with the surrounding 
tissues and increase the survival rate 6. he formalised the 
Position paper
Autologous fat injection to face and neck: from soft 
tissue augmentation to regenerative medicine
Iniezione di grasso autologo nel distretto testa e collo: dall’incremento tissutale 
alla medicina rigenerativa
R.F. Mazzola, G. CantaRella, S. toRRetta, a. SbaRbati1, l. lazzaRi2, l. PiGnataRo
Department of Specialist Surgical Sciences, iRCCS Ca’ Granda Maggiore Foundation, Polyclinic Hospital, University 
of Milan, Milan; 1 Human anatomy and Histology Section, University of Verona, Verona; 2 Cell Factory, Centre for 
transfusion Medicine, Cell therapy and Cryobiology, Department of Regenerative Medicine, iRCCS Ca’ Granda 
Maggiore Foundation, Polyclinic Hospital, Milan, italy
SummAry
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riASSunTo
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introduzione, quali l’iniezione di grasso autologo per il trattamento della sindrome di Frey post-parotidectomia e dell’insufficienza velo-
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steps of the procedure, christened it lipostructure® 7 and, 
since then, the outcomes of various applications, such as 
restoring fullness, correcting asymmetries and scars, etc., 
have improved considerably and there has been a dramatic 
decrease in the reabsorption rate.
recent studies on the extracellular matrix have shown that 
fatty tissue not only contains adipocytes, but also pre-adi-
pocytes, endothelial cells, fibroblasts and adipose-derived 
adult mesenchymal stem cells (AdSCs) that are capable 
of differentiating into many lineages, thus indicating that 
fat can provide a basis for soft tissue regeneration 8 9. Al-
though only recent, it already seems that the idea of use of 
AdSCs for reconstructive and functional purposes is like-
ly to affect various fields of head and neck surgery 10-14.
The aims of this report are: 1) to outline the basic princi-
ples underlying autologous fat injections (AFis) and their 
implications for regenerative medicine; 2) to describe the 
technical details of fat harvesting, purification and place-
ment; and 3) to provide otolaryngologists with an over-
view of the various functional and aesthetic uses of AFis 
in the face and neck.
Basic principles of fat grafting
Adipose-derived stem cells
The most promising research, in the field of regenerative 
medicine, involves the use of totipotent, pluripotent and 
multi-potent stem cells: i.e., undifferentiated cells with 
significant self-renewal capacities. Totipotent stem cells, 
which can be obtained starting from the blastocyst stage, 
are capable of triggering various human cell lineages, in-
cluding human embryonic stem cells (heSCs); pluripo-
tent stem cells can differentiate into any of the: endoderm, 
mesoderm or ectoderm germ layers (i.e., induced pluripo-
tent stem cells,); and multi-potent stem cells can produce 
daughter cells of a limited number of lineages, including 
haematopoietic progenitor cells that can develop into dif-
ferent types of blood cells, but not into cell types of other 
origin. There are still a number of major limitations con-
cerning the therapeutic use of heSCs and ipS, including 
ethical concerns, cell regulation and gene defects 15, but a 
number of clinical trials using adult stem cells have shown 
that they can have beneficial clinical effects 16.
Friedenstein et al. 17 were the first to discover that bone 
marrow  contains  cells  that  can  differentiate  into  other 
mesenchymal cells as well as into fibroblasts. A few hours 
after placing whole bone marrow in plastic culture dishes, 
they removed the non-adherent cells (and, therefore, most 
of the haematopoietic cells) and found that, although the 
remaining cells were heterogeneous in appearance, the 
most  tightly  adherent  cells  were  spindle-shaped.  They 
also found that the cells could differentiate into colonies 
that resembled small deposits of bone or cartilage. These 
observations were extended by other Authors, through-
out the 1980s 18, who established that cells isolated us-
ing Friedenstein’s method 17 were multi-potent and could 
differentiate  into  osteoblasts,  chondrocytes,  adipocytes 
and even myoblasts. These adherent cells are currently re-
ferred to as mesenchymal stem cells (mSCs), because of 
their ability to differentiate into mesenchymal-type cells, 
or marrow stromal cells, because they appear to arise from 
the complex array of supporting structures found in bone 
marrow.
Bone marrow has long since been the main source of 
mSCs, but these cells account for only a small percentage 
of the cells found in bone marrow. The other most com-
mon source of mSCs is adipose tissue, which not only 
offers an abundant and easily accessible source of AdSCs 
(Fig. 1), but can also be harvested by means of a minimal-
ly-invasive procedure and be processed for clinical appli-
cations in accordance with current good manufacturing 
practice guidelines.
human mSCs are typically isolated retrospectively from 
the mononuclear cell layer of bone marrow after separa-
tion by means of density gradient centrifugation, but they 
can be isolated from the stromal vascular fraction of adi-
pose tissue by digesting the whole tissue with collagenase. 
Fat tissue can contain even more stem cells per gram than 
bone marrow (5000 vs. 100-1000 cells) 19. Some in vivo 
and in vitro studies have shown that AdSCs come from 
vessel-associated pericytes, which are in contact with the 
intimal surfaces of small vessels within the tissue and, if 
sorted and cultured over the long term, give rise to ad-
herent multi-lineage progenitor cells with the features of 
mSCs.
mSCs are phenotypically heterogeneous in terms of mor-
phology, physiology and surface antigen expression. no 
specific marker has yet been identified that exclusively 
characterises mSCs, which express a large number of ad-
hesion molecules, extracellular matrix proteins, cytokines 
and growth factor receptors. As stem cells are character-
ized by their ability to self-renewal and differentiate to-
wards multiple cell lineages, a further way of identifying 
Fig. 1. Multipotent adipose-derived mesenchymal stem cells.Autologous fat injection to face and neck
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possible mSC populations is by inducing them to differ-
entiate into bone, fat and cartilage in vitro. mSCs from 
different  sources  have  been  successfully  differentiated 
into  osteoblasts,  chondrocytes,  adipocytes,  fibroblasts, 
myoblasts  and  cardiomyocytes,  hepatocytes,  tenocytes, 
and even neurons.
Some mSCs  are  already  used  for  orthopaedic,  cardiac 
and neuro-repair, while others are being investigated. it 
is known that mSCs home in on injured or pathological 
tissues by means of still unknown mechanisms but that 
possibly involve chemokines and their receptors, as well 
as adhesion molecules.
Stem cell niche therapy using adipose tissue
A niche refers to the complex relationships that AdSCs 
establish with all of the physiological or ectopic factors 
contributing to determine their identity and fate. A cell 
niche not only applies to interactions with neighbouring 
cells or the surrounding extracellular matrix, but also to 
long-distance interactions through circulating blood, the 
lymphatic system and nerve pathways. The phenotypical 
identity of any cell and its reaction to a given stimulus 
are, therefore, not only determined by the genetic or epi-
genetic equipment of the cell, but also depend on the spe-
cific niche context in which it resides. A change in niche 
parameters or the transplantation of cells into other niches 
can have a considerable effect on cell physiology and alter 
its properties.
The concept of a niche as a specialised micro-environ-
ment housing stem cells was first proposed by Schofield 20 
almost 30 years ago with reference to mammalian hae-
matology. Although this field of stem cell biology is still 
young and very unclear, a number of aspects have been 
clarified for certain stem cell populations and provides 
reference points for defining a common stem cell niche 
paradigm. The best-known stem cell niche is that of hae-
matopoietic stem cells (hSCs) 21 and, although their role 
is still not completely understood, it is known that the sig-
nals transduced by members of the wingless (wnt) family 
are involved in hSCs homeostasis and fate 22.
research has shown that the signals controlling the em-
bryonic origin of AdSCs and their differentiation in adult 
adipose tissue include the same pathways as those in-
volved in the homeostasis of other adult and embryonic 
stem cell populations 23, and their complex orchestration 
can have different effects depending on the concentration, 
stage of differentiation and extrinsic niche factors, such 
as cell-matrix and cell-cell interactions, the presence of 
vasculature, and the level and type of innervation. de-
spite extensive research into the intracellular signalling 
involved in AdSC homeostasis and differentiation, little 
is known about the role of cell-cell and cell-matrix inter-
actions. Zannettino et al. 24 have suggested that AdSCs 
reside in perivascular niches, which prompts the specu-
lation that perivascular structures (cells and extracellular 
matrix) may provide signals that balance the maintenance 
of AdSCs in an undifferentiated state and their commit-
ment to differentiation.
it has recently been shown that in vitro culture and ex-
pansion significantly alter the transcriptional phenotype 
of AdSCs.  Freshly  isolated  stromal  vascular  fractions 
(SvF) express haematopoietic markers (Cd34) that are 
lost within a few days of culturing 25. in line with previ-
ously published findings 26 27, we have found the increased 
expression of mesenchymal stem cell-associated markers 
in cultures of both in human and murine AdSCs, whereas 
the longer term loss of markers of undifferentiated sta-
tus, such as undifferentiated transcription factor (uTF-1), 
indicated a shift towards differentiation. prolonged cul-
turing also significantly down-regulated various isoforms 
of pro-collagen, matrix metallopeptidases and inflamma-
tory cytokines, thus indicating adaptation to the artificial 
environment. under extreme conditions, it has even been 
shown that prolonged in vitro culturing can induce the 
neoplastic transformation of AdSCs 28, although it is still 
unclear whether these changes are reversible or how they 
may affect the therapeutic potential of the cell. however, 
AdSCs can be used in many clinical applications (par-
ticularly in the fields of plastic and reconstructive surgery) 
by means of transplantation without removing them from 
their fat niche.
in addition to molecular and cell biology, the dynamic 
and regenerative nature of fat grafts has been established 
in various areas of plastic surgery, and clinical practice 
has shown that the long-term outcomes of fat grafting can 
include rejuvenation of skin texture 29-32. The ‘regenera-
tive protocols’ used in the pioneering work of Coleman 
included centrifuging fat at 3000x g before transplanta-
tion with the aim of reducing fat volume and removing 
as much debris, oil, blood and water as possible without 
significantly damaging the tissue to be transplanted 33.
ultrastructural studies of centrifuged fat have revealed that 
mature adipocytes show interruptions in their cytoplasmic 
membrane and various degrees of degeneration including 
cell necrosis, but the SvF appears to be well preserved 34. 
rigotti et al. 34 compared the ultrastructure of mammary 
radio-lesions before, and at different times after, fat graft-
ing, and found clear signs of ongoing regeneration, with 
evidence of new adipocyte formation and a large number of 
precursors at different stages of differentiation toward the 
adipocyte phenotype. Before transplantation, almost all of 
the adipocytes were seriously damaged by centrifugation 
and, in the radio-damaged recipient tissue, there were nei-
ther mature adipocytes nor differentiating pre-adipocytes. 
reasonable interpretations of these findings are that the dif-
ferentiating pre-adipocytes observed after treatment were 
either adipocyte-committed AdSCs originally embedded 
within the transplanted fat, or locally present endogenous 
adipocyte-committed AdSCs activated by the ectopically 
transplanted  fat.  The  massive  survival  of AdSCs  in  fat r.F. mazzola et al.
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transplants, despite liposuction and centrifugation proce-
dures, strongly supports the first hypothesis, but the sec-
ond may be equally valid as it assumes that transplanted fat 
enriched with AdSCs by centrifugation can behave as an 
atypical ectopic niche that orchestrates tissue regeneration 
by modulating endogenous tissue resources.
The term ‘atypical ectopic niche’ could be used as a com-
mon paradigm of stem cell-based therapies. it is based on 
the idea of a ‘bystander’ mechanism in which the stem 
cells ectopically transplanted into a generic lesion (radio-
lesion, myocardial infarction, cerebral stroke, etc.) do not 
replace tissue-specific cells by direct differentiation, but 
locally form an atypical stem cell niche that suppresses 
inflammation,  promotes  neo-angiogenesis,  and  favours 
the activation of endogenous stem cell precursors by re-
leasing trophic factors, such as cytokines, pro-angiogenic 
molecules and growth factors.
Clinical applications of fat grafting
Fat  harvesting,  purification,  placement  and  complica-
tions
Fat harvesting
usually 50 cc of lipoaspirate are sufficient to solve face 
and neck problems, but 10-12 cc are enough in many cas-
es involving vocal folds, scars or fistulae. however, it may 
sometimes be difficult to obtain enough material as recon-
structive surgeons often have to treat thin patients. The 
choice of the site of harvesting is, therefore, extremely 
important. The primary source is the lower abdomen, fol-
lowed by the inner thigh and the inner knee (we generally 
prefer to avoid the lateral thigh or Bichat fat pad because 
of possible post-operative asymmetries or deformities).
The basic harvesting equipment includes a 3 mm diame-
ter, 15 cm long, 2-hole distal opening blunt-tipped cannu-
la (Byron medical, Tucson, AZ, uSA), a 10 cc luer-lock 
syringe, and a backhouse towel forceps. The selected area 
is infiltrated with 10-15 cc of a solution of 2.0% carbo-
caine with 1:200,000 epinephrine. A 2 mm stab incision, 
large enough to allow the insertion of the cannula con-
nected to the syringe, is made in the inferior pole of the 
umbilicus using a no. 11 blade. when inserting the can-
nula for fat harvesting, it is essential to pinch the skin 
firmly between the thumb and fingers in order to avoid 
penetrating the abdominal cavity or the saphenous vein 
(if the inner thigh is used). The plunger of the syringe is 
gently retracted to provide negative pressure, throughout 
the suction manoeuvre using a backhouse towel forceps 
(Fig. 2). The procedure should be the least traumatic pos-
sible in order to avoid damaging the fragile adipocytes. 
once the necessary amount of fat is obtained, the stab in-
cision is closed using one or two 5/0 ethilon stitches. it is 
advisable to use an elastic garment to reduce the risk of 
haematoma in the donor area.
Purification
Separating  the  different  lipoaspirate  components  is  es-
sential. The purification equipment includes a centrifuge 
with a sterilisable central rotor, metal sleeves to hold the 
10 cc luer-lock syringes, plastic plugs for locking them, 
a rack for holding them, Codman neuropads, and a three-
way tap. The plugged syringes are placed in the centri-
fuge, protected by sterile metal sleeves. The lipoaspirate 
is centrifuged at 1,200 j for 3’ to separate three compo-
nents: the upper layer mainly consists of oil from ruptured 
adipocytes; the middle layer includes viable adipocytes; 
and the lower, mainly aqueous, layer contains blood, car-
bocaine, etc. The upper layer is discarded using the Cod-
man neuropads, and the aqueous component is released 
by removing the plug from the syringe. A three-way tap is 
then used to transfer the refined fatty layer a 3.0 cc luer-
lock syringe for placement.
Placement
The placement equipment includes not only a 3.0 cc luer-
lock syringe, but also various types of 18 gauge blunt, 
straight or curved, 9 cm long style i and ii Coleman can-
nulas, and an 18 gauge v-shaped dissector Coleman can-
nula (Byron medical, Tucson, AZ, uSA). Correct place-
ment is crucial, and pre-surgical markings are made in a 
sitting position to highlight the areas in which the fat is 
to be inserted. Fat grafting is usually performed under lo-
cal anaesthesia with sedation, great care being taken to 
ensure sterility at all times since bacterial contamination 
may cause infection and the complete loss of the trans-
planted fat. in our protocol, a prophylactic antibiotic is 
routinely administered intravenously during the operation. 
To maximize contact between the graft and the surround-
ing tissue, it is essential to create multiple tunnels running 
in different directions so that a minimum number of fat 
Fig. 2. Fat harvesting from the abdomen (A); fat purification by means of 
centrifugation (B); lipoaspirate after centrifugation: note the three different 
layers (C);removal of oily and aqueous components from the fatty layer (D); 
the refined fatty layer is then transferred to a 3.0 cc Luer-lock syringe by 
means of a three-way tap (E); lipoaspirate ready to be injected (F).Autologous fat injection to face and neck
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parcels can be slowly positioned upon cannula withdraw-
al. A bolus should be avoided because the insufficiently 
vascularised graft core will inevitably die, leading to liq-
uefaction and necrosis, as well as unsightly irregularities 
or cysts. Choosing the appropriate cannula is important: 
an 18 gauge blunt style 1 or 2 Coleman cannula with only 
one hole at the distal end allows the least traumatic crea-
tion of the tunnels and also minimizes the risk of damag-
ing vessels or nerves. however, in the presence of scars, 
contractures or fibrous tissue, a sharp v-shaped dissector 
cannula is necessary as it disrupts adhesions between the 
skin and the underlying structures while creating a cavity. 
An alternative means of releasing the skin from the dermis 
is to make continuous clockwise and counter-clockwise 
movements with a sharp 16-18 gauge bevelled needle to 
sever fibrotic adherences and to create a plane in which 
the adipocytes can be deposited.
After following the basic principles for correct placement, 
it is necessary to establish the appropriate depth of the 
graft as the level of infiltration varies in each anatomical 
area: an immediate subcutaneous plane along the cheek; 
which  should  be  very  superficial  around  the  chin  and 
jawline to avoid damaging the marginal branch of the fa-
cial nerve; deeper within the vocalis muscle in the case of 
vocal fold augmentation; and very superficially for filling 
depressions or correcting scar contractures or radioder-
matitis. The amount injected should be recorded.
patients should be told that a second, and sometimes a 
third, procedure at 3-4 month intervals may be necessary 
to achieve the ideal volume.
Complications
Fat grafting can be performed as an outpatient procedure 
with  little  morbidity  and  few  complications.  however, 
as with any surgical technique, problems can arise. Care 
must be taken to avoid potentially life-threatening gut per-
foration during harvesting (especially in thin patients) by 
pinching the skin before inserting the cannula. An intra-
vascular fat injection can lead to pulmonary embolism, 
stroke or blindness, but this can be avoided by using small 
blunt cannulas for soft tissue dissection and fat place-
ment 35. meticulous asepsis is essential to prevent infec-
tions. Finally, in order to avoid adipocyte rupture, leading 
to unpleasant oily cysts, minimal amounts of fat should be 
homogeneously placed in multiple tunnels 35.
AFI to the face and neck
Congenital malformations
AFi may be useful to treat some congenital malformations 
(including facial asymmetry in patients with hemifacial 
microsomia) and the post-surgical sequelae of cleft lips.
in  patients  with  hemifacial  microsomia,  the  traditional 
treatment  programme  includes  distraction  osteogenesis 
of the hypoplastic mandible at an early age, and leFort1 
Fig. 3. Sequela of tracheostomy (A); the same patient after autologous fat 
injection (two procedures for a total amount of 10 cc) (B).
osteotomy with sagittal splitting of the mandible and a 
contralateral costochondral graft and sliding genioplasty 
at completing of growth. in either case, the residual facial 
asymmetry, due to soft tissue deficit, can be corrected by 
repeated AFis (at least 3 sessions at 4-month intervals, for 
a total of 60 cc), which lead to nearly normal symmetry 
and more predictable results than dermal fat grafts or use 
of implants.
in the case of cleft lips, AFi (generally two sessions for 




The frequent aesthetic and sometimes functional sequelae 
of tracheostomy can create concern.
management traditionally requires the surgical transpo-
sition of surrounding tissue to fill the depression, and 
the use of local flaps to close the soft tissue defect once 
the scars have been excised. on the basis of our expe-
rience, AFi can be used to improve the sequelae due 
to fibrotic bands between the skin and underlying tis-
sue and correct hypertrophic scars (Fig. 3). This simple 
and repeatable procedure (usually three sessions) can 
be performed under local anaesthesia obtained by infil-r.F. mazzola et al.
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trating 2.0% carbocaine with a 1:200,000 epinephrine 
solution. The fibrotic bands between the skin and tissue 
can be interrupted by inserting an 18 gauge sharp needle 
subcutaneously and moving the tip clockwise and coun-
ter-clockwise, taking care not to leave an excessively 
large  dead  space  that  would  reduce  contact  between 
the adipocytes and surrounding tissue. later, using a 
sharp v-shaped dissector cannula, AFi is performed by 
means of multiple radial infiltrations between the skin 
and subcutaneous tissue. The first session usually only 
corrects the depression (total amount 5 cc) and, if the 
tissue is still recessed, a further 3-4 cc can be delivered 
after 4 months to improve scarring retraction, increase 
tissue volume and restore eutrophic skin. After a further 
4 months, the residual scar is excised to obtain a better 
aesthetic result.
Pharyngo-cutaneous fistulae
pharyngo-cutaneous fistulae are quite common seque-
lae of the surgical treatment or radiotherapy of head and 
neck cancer. large fistulae or pharyngostomes should 
be closed using local or distant flaps (direct suturing in-
evitably fails and may also increase the size of the fis-
tula) but small fistulae can be treated with AFi (Fig. 4). 
The procedure is simple and does not require any spe-
cial pre- or post-operative care. under local anaesthe-
sia, 2-2.5 cc of adipocytes are placed between the skin 
and mucosa, at a distance of 1 cm all around the fistula, 
using an 18 gauge blunt style i cannula. After 6 weeks, 
there is an improvement in skin texture and quality, with 
an increase in the volume of the dystrophic tissue. The 
residual fistula is closed by directly closing its margins 
in a double layer.
Sequelae of radiotherapy
The well-known dramatic consequences of radiother-
apy on the head and neck lead to soft tissue deteriora-
tion and skin atrophy, particularly in children. instead 
of invasive and often unpredictable major surgery, re-
peated AFi (generally 2-3 sessions) can provide suf-
ficient bulk to the affected side of the face. it is also 
useful in making the previously stiff and atrophied skin 
softer and more pliable, and improving its texture and 
colour match.
Sequelae of rhinoplasty
Fat grafting to the nose is a challenging means of improv-
ing rhinoplasty results. The most obvious indications are 
to correct the contours of the dorsum in the case of saddle 
nose deformity, camouflage cartilage or bone irregulari-
ties, or provide better skin texture in the case of atrophy 
or scarring. it may also improve airway obstruction when 
placed at the level of the nasal valve 36.
Between 0.5 and 2.5 cc of fat should be injected into mul-
tiple intradermal or subcutaneous tunnels depending on 
the type of defect. The wounds are dressed using steri-
strips for 10-15 days in order to avoid fat displacement.
Sequelae of burns
it  is  always  difficult  to  improve  the  facial  scarring 
caused by burns both functionally and aesthetically, but 
repeated AFi (usually 2-3 sessions at 4-month intervals) 
can lead to better skin texture, scar quality and skin col-
our, and also increase volume in retracted areas and re-
establish gliding tissue, thus improving the contractures 
and limited mobility caused by fibrotic tissue and skin 
graft adhesions. The use of a sharp v-shape dissector 
cannula is recommended to reduce the fibrosis and inter-
rupt subcutaneous adhesions, and only small amounts of 
fat should be placed under the skin graft to avoid the risk 
of fat necrosis.
Vocal fold augmentation
Fat auto-grafting in the vocal folds, to correct defective 
closure, was first described in the early 1990s by mikae-
lian et al. 37 and Brandenburg et al. 38, who reported the suc-
cessful treatment of unilateral laryngeal paralysis. Subse-
quently, various authors used fat grafting to treat glottic 
incompetence but, as most of them found that reabsorption 
caused long-term failure 39-41, vocal fold fat augmentation 
was considered to be only a temporary solution and was 
abandoned in favour of prosthetic implants 42 or injectable 
alloplastics. Both absorbable materials such as collagen 43 
or hyaluran derivatives 44, and permanent fillers have been 
used but it has been shown that non-resorbable implants 
such as Teflon and silicon have a tendency to migrate and 
cause foreign body reactions 45, and that “biomaterials” 
such as collagen can cause delayed hypersensitivity reac-
tions 46 and vocal fold stiffness due to fibrosis 47. As an 
alternative to injections, vocal folds can be successfully 
increased by deeply burying a typically silicon prosthetic 
implant after fenestrating the thyroid cartilage 42. how-
ever, this “thyroplasty” requires an external approach that 
causes an anterior cervical scar, and may also be followed 
by implant extrusion 48.
The  advent  of  liposuction  made  autologous  fat  easily 
available, and aroused new interest in using AFi to aug-
ment paretic or defective vocal folds. Furthermore, recent 
basic research has shown that fat is a vital organ and that 
its stromal vascular fraction contains cells displaying the 
Fig. 4. Pharyngo-cutaneous fistula after total laryngectomy (A); autologous 
fat injection (total amount 2.5 cc) (B); complete closure of pharyngo-cutane-
ous fistula four months after the procedure (C).Autologous fat injection to face and neck
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typical features of mSCs 49 capable of self-renewal and 
differentiation into multiple cell lineages 13 50 51. The main 
indications for vocal fold AFi are shown in Table i. After 
harvesting and purification (as described above), fat par-
cels are introduced into the barrel of a pistol (medtronic, 
micro-France, Jacksonville, Fl mCl-55) using a 1 mm 
diameter bayonet needle, with air exposure being mini-
mised to avoid cytoplasmic lysis 7. in the case of vocal 
fold paralysis, the fat is injected deeply into the paralysed 
vocalis muscle, usually starting at the posterior third under 
direct microlaryngoscopy and general anaesthesia. The 
injection is made while retracting the needle in order to 
allow the fat to diffuse in layers. in patients with scarring 
or congenital soft tissue defects, the injections are made in 
the vocalis muscle and a number of sites in the superficial 
layer of the lamina propria (reinke’s space) depending 
on the aetiology and severity of the glottic incompetence. 
in cases of sequelae of cordectomy, AFi might also be 
placed in the paraglottic space in order to enhance medi-
alization. The aim of injecting the superficial layer is to 
free adherent tissue in the cover and restore the gliding 
layer in which the mucosal wave flows to produce sound. 
injecting areas of scar tissue also undermines the epithe-
lium while softening the scar itself (Fig. 5). it is difficult 
to quantify the amount of grafted fat exactly as some of it 
oozes out while removing the needle, but we estimate that 
1-3 cc are injected for each vocal fold treated. paralytic 
vocal folds are overcorrected until their volume approxi-
mately doubles (if both vocal folds are treated, only one 
is over-inflated).
on the basis of our experience, AFi is simple and effec-
tive,  and  leads  to  good  and  stable  voice  improvement 
without the risk of a foreign body reaction inducing vo-
cal fold stiffness, and without impairing inspiratory and 
expiratory flows 52. The fat obtained by liposuction is soft 
and easily diffuses into the vocal fold layers, and therefore 
it does not alter the elasticity of the glottic vibrator even if 
injected into reinke’s space because the viscosity is simi-
lar to that of reinke’s space 53. however, despite these fa-
vourable characteristics, the role of vocal fold fat injection 
is still debated mainly because of its unpredictable reab-
sorption. nevertheless, in our opinion maximizing contact 
between the fat parcels and host tissue, by injecting the fat 
into several layers, favours fat cell nutrition, oxygenation 
and integration, and leads to stable results 54.
Furthermore,  it  has  been  shown  that AFi  may  relieve 
swallowing impairment due to defective sphincteric clo-
sure of the larynx following previous surgery or paralytic 
incompetence 10 55 56.
Frey syndrome
Frey syndrome consists of profuse sweating and cutane-
ous flushing in the area innervated by the auriculotemporal 
nerve. it frequently occurs after parotidectomy probably 
because of misdirected resprouting of the post-ganglionic 
parasympathetic  fibres  feeding  the  parotid  gland  to  the 
cutaneous sweat glands 57. The incidence of the subjective 
clinical occurrence of post-parotidectomy Frey syndrome 
(ppFS) is 10-40% 58 depending on the case series, but most 
patients show a positive objective reaction to the diagnos-
tic minor’s iodine starch test 58 59. many forms of treat-
ment have been proposed, including the local application 
of anti-cholinergic ointments 58 or multiple intra-cutaneous 
Table I. Indications for autologous fat injection of vocal folds.
Indications for autologous fat injection of vocal folds
Unilateral laryngeal paralysis or paresis
Malformations of the vocal fold structure (sulcus glottidis or vergeture)*
Scarring due to previous surgery (for benign or malignant lesions of the vocal folds)
Scarring due to prolonged intubation or laryngeal fracture/contusion
Vocal fold atrophy due to previous radiotherapy
Secondary procedure following failure of previous augmentation by means of injection or prosthetic implant (with possible inflammatory reaction and 
secondary tissue stiffness).
* Congenital adherence of the epithelium to the ligament with lack of gliding tissue in Reinke’s space.
Fig. 5. Videolaryngoscopic images in a 37-year-old female, with a 10-
month history of post-thyroidectomy right vocal fold paralysis. Pre-operative 
view of vocal folds on inspiration (A) and on phonation (B), N.B. The wide gap 
of glottic closure due to hypotrophy and flaccidity of the right paralyzed fold. 
Result 3 months’ post-operatively: the right fold still has a yellowish colour 
(C), and complete glottic closure is achieved during phonation (D).r.F. mazzola et al.
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botulinun toxin A injections 60 61 and traditional and more 
invasive  surgical  procedures  such  as  timpanic  neurecto-
my 62 or the interposition of an autologous graft (dermal, 
the temporoparietal fascia) 63 to create a barrier between the 
skin and the residual parotid gland. however, as the former 
are only partially and transiently effective in most cases, 
and the latter involve the risk of possible facial nerve in-
jury 58, there is still no treatment of choice 58. on the basis 
of the encouraging results obtained in other fields, such as 
aesthetic surgery, and the experience of Curry et al. 64 who 
have used autologous fat graft reconstruction with superfi-
cial musculo-aponeurotic system elevation as prophylaxis 
for Frey syndrome, autologous AFi in the parotid area may 
be a minimally-invasive option as the fat would create a 
barrier between the skin and the residual parotid gland, and 
may prevent abnormal nerve neo-anastomoses to the sweat 
glands. in addition to being useful for treating the unpleas-
ant salivary sweating and flushing typical of ppFS, AFi 
could also have a positive aesthetic impact as it may fill the 
gap left by the excision of the parotid. it can be performed 
in a one-day-surgery setting with the patients under local 
anaesthesia and sedation, but needs to be preceded by care-
fully marking of the whole of the affected area identified 
by minor’s iodine starch test 59 (Fig. 6). This consists of ap-
plying an iodine solution (iodine 1.5 g, castor oil 10 g, and 
95% ethanol 125 ml) to the parotid skin surface, and then 
sprinkling it with white starch powder; when the patient 
starts to eat, sweating in the skin areas affected by ppFS 
turn  the  white  solution  to  dark  purple. we  recommend 
marking the affected area with a 1 cm grid drawn on the 
patient’s skin, and labelling the more intensely coloured ar-
eas with a “+”. Some standardised clinical scores have been 
suggested to assess the severity of the syndrome, including 
that of luna-ortiz et al. 65, which evaluates the objective 
clinical extent of the affected area (determined on the basis 
of minor’s iodine starch test) and the subjective impact of 
ppFS on the patients’ quality of life. once the pre-operative 
marking has been completed, fat is harvested as described 
above. The dark purple part of the parotid area is then care-
fully infiltrated with a 1:200,000 carbocaine:epinephrine 
mixture, and a 2 mm stab incision is made 3 mm in front of 
the ear lobe (carefully avoiding the facial nerve) and a 19 
gauge Coleman v-shaped dissector is carefully and gently 
inserted to dissect into a sub-dermal plane (once again tak-
ing care not to damage the underlying facial nerve). The 
adipocytes transferred into a 19 gauge Coleman style ii 
cannula are then medially placed by means of a gentle dis-
section into the immediate sub-dermal plane. using Cole-
man’s technique 14, the adipocytes are deposited in multiple 
tunnels created by advancing the cannula to the most distal 
site and retracting it to the proximal site in more than one 
direction, with the fat being continuously injected while re-
tracting the cannula. more fat is injected where the staining 
is darkest (the squares labelled “+”). The procedure also 
includes fat graft deposition to fill the post-auricular area 
by means of a 1-2 mm stab incision. minimally-invasive 
AFi of the parotid area can be considered safe and effective 
in ppFS, and also has an aesthetic impact as it can fill the 
gap left by the parotid gland excision (Fig. 7). however, 
patients should be informed that the procedure may need 
to be repeated to achieve a definitive result, although this 
limitation  may  be  overcome  by  scrupulously  respecting 
the pre-operative grid and using multiple tunnels for place-
ment. Furthermore, when indicated, subsequent procedures 
can be performed in a one-day setting under local anaesthe-
sia with minimal patient discomfort.
Velo-pharyngeal insufficiency
velo-pharyngeal insufficiency (vpi) is most frequently due 
to congenital soft palate abnormalities (mainly a sequela 
Fig. 7. Pre-operative Minor’s iodine starch test in a patient with PPFS (A). 
The same patient 2 months after AFI of the parotid area (total amount 24 cc): 
the area affected by Minor’s iodine starch test is markedly smaller and the 
gap left by the parotid excision has been filled (B).
Fig. 6. Pre-operative Minor’s iodine starch test in a patient with PPFS: an 
iodine solution is applied to the parotid skin surface (A), and the skin is then 
sprinkled with white starch powder (B). When the patient starts to eat, the 
white iodine solution on the skin areas affected by PPFS becomes dark pur-
ple as a result of sweating (C). The affected area is marked with a 1 cm grid 
drawn on the patient’s skin, and the most intensely coloured areas are la-
belled with a “+” (D).Autologous fat injection to face and neck
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of cleft palate repair), but may also be due to neurological 
causes (paralysis or paresis) or acquired conditions. Surgi-
cal treatment is traditionally based on velopharyngoplast-
ies, including local flaps, sphincter reconstruction or the 
advancement of the posterior pharyngeal wall, which are 
adopted to narrow the passage between the naso- and oro-
pharynx 66. velopharyngoplasties lead to excellent results in 
terms of reducing hypernasality and improving voice reso-
nance and speech articulation, but may also cause post-op-
erative pain and bleeding 67. post-operative snoring is also 
frequent, and obstructive sleep apnoea can be a transitory 
or persistent sequela 68 69. The use of implants to increase 
the posterior pharyngeal wall has been proposed as a less 
invasive alternative to major surgical procedures, but non-
reabsorbable  materials,  such  as  hydroxyapatite,  goretex 
or silicone, can be associated with migration and extru-
sion, and re-absorbable materials only lead to a temporary 
improvement 70. The transplantation of autologous tissue 
can avoid these drawbacks 71. Fat grafting in the posterior 
pharyngeal wall, using an external approach, was origi-
nally suggested by gaza in 1926 72, but was subsequently 
abandoned. The advent of liposuction led to autologous fat 
grafts being proposed as a means of increasing the posterior 
naso-pharyngeal wall in patients with moderate vpi 71 73 74
AFi  is  performed  under  general  anaesthesia  with  oral 
endo-tracheal intubation. A digman mouth gag is used to 
expose the naso-pharynx, and the soft palate is retracted 
by means of two rubber catheters passing through the na-
sal fossae to the mouth with their ends tied. A 70° Storz 
4 mm nasal endoscope connected to a videocamera is in-
serted through the mouth to visualise the nasopharynx, 
and 3-5 stab incisions are made in the posterior oropha-
ryngeal wall using an 11 blade. A 7 cm long, 1.5 mm di-
ameter, malleable blunt cannula (pouret médical, Clichy, 
France) is inserted and gently advanced to create multi-
ple tunnels upwards towards the atlas prominence. After 
harvesting and purification, as described above, the fatty 
tissue grafts are placed under endoscopic guidance while 
withdrawing the cannula in the submucosal and the intra-
muscular tissue of the superior constrictor muscle, taking 
care to remain above the pre-vertebral fascia. The injec-
tions are made in multiple layers as often as possible in 
order to maximize surface contact with the host tissue and 
improve survival 14 75. A stab incision is then made in the 
midline (cephalad to uvula) of the nasal surface of the ve-
lum, and the fat is injected (particularly distally and on the 
midline scarred tissue of cleft palate patients). Between 
3.5 and 8 cc of fat is used for each patient.
on  the  basis  of  our  preliminary  experience, AFi  is  a 
straightforward and minimally-invasive means of treating 
vpi that significantly reduces hypernasality and improves 
overall  speech  quality  in  paediatric  and  adult  patients. 
however, a longer follow-up is needed to confirm these 
findings, and patients should be informed that multiple 
procedures might be needed to optimise the results; in the 
case of incompleteness, subsequent velo-pharyngoplasties 
can be performed as AFi does not affect them.
Conclusions
on the basis of the presence of multi-potent AdSCs and 
our experience using AFi in the head and neck region, 
we believe that it is a safe and minimally-invasive pro-
cedure both for functional and aesthetic purposes, and a 
valid alternative to major surgery. The clinical applica-
tions of AFi now include fat grafting to the face, vocal 
fold augmentation for glottic incompetence, the treatment 
of post-parotidectomy Frey syndrome, and velo-pharyn-
geal insufficiency. vocal fold augmentation for glottic in-
competence has been standardized and used in our Clinic 
for several years, whereas using AFi to treat pharyngo-
cutaneous  fistulae  after  head  and  neck  cancer  surgery, 
post-parotidectomy Frey syndrome and velo-pharyngeal 
insufficiency are more recent proposals that have led to 
positive outcomes.
hopefully the present report will encourage further stud-
ies on the effectiveness of AFi in other fields.
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